TY - JOUR
T1 - Suppressor of cytokine signaling-1 ameliorates dextran sulfate sodium-induced colitis in mice
AU - Horino, Jiro
AU - Fujimoto, Minoru
AU - Terabe, Fumitaka
AU - Serada, Satoshi
AU - Takahashi, Tsuyoshi
AU - Soma, Yoshihito
AU - Tanaka, Kentaro
AU - Chinen, Takatoshi
AU - Yoshimura, Akihiko
AU - Nomura, Shintaro
AU - Kawase, Ichiro
AU - Hayashi, Norio
AU - Kishimoto, Tadamitsu
AU - Naka, Tetsuji
PY - 2008/6
Y1 - 2008/6
N2 - Inflammatory bowel disease (IBD) is a chronic disorder of the gastrointestinal tract. Although the etiology and pathogenesis of IBD remain unknown, pro-inflammatory cytokines including IFN-γ play an important role in the development of IBD. Suppressor of cytokine signaling-1 (SOCS-1) is a crucial inhibitor of cytokine signaling, particularly of IFN-γ. In this study, we investigated the role of SOCS-1 in the development of murine dextran sulfate sodium (DSS)-induced colitis, a model of colitis resembling human IBD. SOCS-1 heterozygous (SOCS-1+/-) and wild-type (WT) mice were given 3% DSS dissolved in drinking water for 5 days. Activation and expression of signal transducers and activators of transcription (STAT) in colonic tissues were assessed by western blot analysis. The expression of CD4, IFN-γ, IL-4, IL-17 and Forkhead box P3 (Foxp3) in colonic lamina propria lymphocytes was analyzed by flow cytometry and cytokine concentrations in serum were measured. DSS-treated SOCS-1+/- mice developed more severe colitis than DSS-treated WT mice. Enhanced activation of STAT1, a higher ratio of CD4+ IFN-γ+T cells and a lower frequency of Foxp3+ regulatory T (Treg) cells, were observed in the colon of DSS-treated SOCS-1+/- mice compared with DSS-treated WT mice. DSS-treated SOCS-1+/- mice showed higher levels of IFN-γ in sera than did DSS-treated WT mice. Furthermore, T cell-specific SOCS-1-conditional knockout mice developed more severe colitis than control mice after DSS administration. Our findings suggest that SOCS-1, particularly in T cells, prevents the development of DSS-induced colitis in mice by inhibiting IFN-γ/STAT1 signaling and by subsequently regulating Treg cell development.
AB - Inflammatory bowel disease (IBD) is a chronic disorder of the gastrointestinal tract. Although the etiology and pathogenesis of IBD remain unknown, pro-inflammatory cytokines including IFN-γ play an important role in the development of IBD. Suppressor of cytokine signaling-1 (SOCS-1) is a crucial inhibitor of cytokine signaling, particularly of IFN-γ. In this study, we investigated the role of SOCS-1 in the development of murine dextran sulfate sodium (DSS)-induced colitis, a model of colitis resembling human IBD. SOCS-1 heterozygous (SOCS-1+/-) and wild-type (WT) mice were given 3% DSS dissolved in drinking water for 5 days. Activation and expression of signal transducers and activators of transcription (STAT) in colonic tissues were assessed by western blot analysis. The expression of CD4, IFN-γ, IL-4, IL-17 and Forkhead box P3 (Foxp3) in colonic lamina propria lymphocytes was analyzed by flow cytometry and cytokine concentrations in serum were measured. DSS-treated SOCS-1+/- mice developed more severe colitis than DSS-treated WT mice. Enhanced activation of STAT1, a higher ratio of CD4+ IFN-γ+T cells and a lower frequency of Foxp3+ regulatory T (Treg) cells, were observed in the colon of DSS-treated SOCS-1+/- mice compared with DSS-treated WT mice. DSS-treated SOCS-1+/- mice showed higher levels of IFN-γ in sera than did DSS-treated WT mice. Furthermore, T cell-specific SOCS-1-conditional knockout mice developed more severe colitis than control mice after DSS administration. Our findings suggest that SOCS-1, particularly in T cells, prevents the development of DSS-induced colitis in mice by inhibiting IFN-γ/STAT1 signaling and by subsequently regulating Treg cell development.
KW - DSS-induced colitis
KW - IBD
KW - IFN-γ
KW - SOCS-1
KW - Treg
UR - http://www.scopus.com/inward/record.url?scp=44849121674&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=44849121674&partnerID=8YFLogxK
U2 - 10.1093/intimm/dxn033
DO - 10.1093/intimm/dxn033
M3 - Article
C2 - 18381351
AN - SCOPUS:44849121674
SN - 0953-8178
VL - 20
SP - 753
EP - 762
JO - International immunology
JF - International immunology
IS - 6
ER -